For the quarter ending 2026-03-31, HALO made $376,708K in revenue. $150,049K in net income. Net profit margin of 39.83%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 376,708 | 451,767 | 354,264 | 325,719 |
| Cost of sales | 79,238 | 78,770 | 55,242 | 46,359 |
| Amortization of intangibles | 29,512 | 23,376 | 17,762 | 17,762 |
| Research and development | 25,560 | 31,897 | 17,251 | 17,543 |
| Selling, general and administrative | 57,881 | 77,028 | 46,088 | 41,614 |
| Impairment of intangible asset | - | 12,175* | - | - |
| Acquired in-process research and development expense | - | 321,412* | - | - |
| Total operating expenses | 192,191 | 544,658 | 136,343 | 123,278 |
| Operating income | 184,517 | -92,891 | 217,921 | 202,441 |
| Investment and other income, net | 1,318 | 2,430 | 5,333 | 6,891 |
| Inducement expense related to convertible notes | - | 5,477* | - | - |
| Contingent liability fair value measurement gain | - | 0* | - | - |
| Interest expense | 5,508 | 4,911 | 4,296 | 4,394 |
| Income before income tax expense | 180,327 | -100,849 | 218,958 | 204,938 |
| Income tax expense | 30,278 | 40,742 | 43,733 | 39,778 |
| Net income | 150,049 | -141,591 | 175,225 | 165,160 |
| Basic EPS | 1.27 | -1.204 | 1.49 | 1.36 |
| Diluted EPS | 1.22 | -1.156 | 1.43 | 1.33 |
| Basic Average Shares | 118,144,000 | 117,583,000 | 117,219,000 | 121,343,000 |
| Diluted Average Shares | 122,875,000 | 122,483,000 | 122,331,000 | 124,158,000 |
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)